Comparative Analysis of Prognostic Risk Models in Metastatic Renal Cell Cancer

Strategic Insights -

Investigators at Dokuz Eylul University Faculty of Medicine have conducted a study comparing the International metastatic renal cell carcinoma (mRCC) Database Consortium (IMDC), Memorial Sloan Kettering Cancer Center (MSKCC), and Cleveland Clinic Foundation (CCF) risk models in patients with metastatic renal cell cancer who received immunotherapy (IO) and molecular targeted therapy. The researchers analyzed the scores of 180 patients, grouping them as favorable, intermediate, and poor risk based on the IMDC, MSKCC, and CCF risk models. The study found a significant correlation between the three risk models, with median progression-free survival (mPFS) and median overall survival (mOS) rates varying accordingly.

Key Takeaways:

  • The study aimed to reveal the relationship and correlation between the IMDC, MSKCC, and CCF risk models used to determine first-line treatment in metastatic mRCC.
  • The IMDC, MSKCC, and CCF scores of mRCC patients who received IO and targeted therapy were calculated retrospectively at the time of diagnosis.
  • The researchers grouped patients as favorable, intermediate, and poor risk based on the results of the IMDC, MSKCC, and CCF scores.
  • The median progression-free survival (mPFS) and median overall survival (mOS) rates of the patients were calculated and considered to be significantly correlated with each other.
  • The study found that all three risk models were correlated with each other, providing new insights into the management of metastatic renal cell cancer.
  • The research was conducted by investigators at Dokuz Eylul University Faculty of Medicine, with additional authors from the same institution.
  • The study's findings have important implications for the treatment of metastatic renal cell cancer, particularly in patients receiving IO and targeted therapy.

Sources:

  • Comparison of Prognostic Risk Models (IMDC, MSKCC, CFF) in Patients Diagnosed with Metastatic Renal Cell Cancer. Forbes Tip Dergisi, 2025,6(2):180-187. Galenos Yayinevi.
  • NewsRx LLC. Reports on Kidney Cancer Findings from Dokuz Eylul University Faculty of Medicine Provide New Insights [Comparison of Prognostic Risk Models (IMDC, MSKCC, CFF) in Patients Diagnosed with Metastatic Renal Cell Cancer]. Cancer Weekly. August 26, 2025; p 69.